Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group study. - Wikidata - awgldk - TriplyDB

Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group study.

Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group study.

http://www.wikidata.org/entity/Q34163791

about

Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer.Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers.Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis Cost-effectiveness of sentinel node biopsy and pathological ultrastaging in patients with early-stage cervical cancer.

P2860

Q34662652-3FD83130-6FC8-4CA9-A4CE-08B8E327B129 Q36195902-6703AD3B-A811-42B5-BFC9-69A02D1EFB15 Q36347370-D8396CF3-C133-4B61-9097-E1DB621E1E63 Q36868936-33BB3689-C985-4E53-A4C8-1F8CC8A737C9 Q39002072-1DAE63C2-5459-40D3-B8CE-354D3F3A66EA

P2860

Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group study.

http://www.wikidata.org/entity/Q34163791

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Posttherapy residual disease a ...... ecologic Oncology Group study.

@ast

Posttherapy residual disease a ...... ecologic Oncology Group study.

@en

Posttherapy residual disease a ...... ecologic Oncology Group study.

@nl

type

label

Posttherapy residual disease a ...... ecologic Oncology Group study.

@ast

Posttherapy residual disease a ...... ecologic Oncology Group study.

@en

Posttherapy residual disease a ...... ecologic Oncology Group study.

@nl

prefLabel

Posttherapy residual disease a ...... ecologic Oncology Group study.

@ast

Posttherapy residual disease a ...... ecologic Oncology Group study.

@en

Posttherapy residual disease a ...... ecologic Oncology Group study.

@nl

P1433

Q34163791-3E0C619A-4DE2-48EC-B709-063AC2021ABD

P1476

Q34163791-33436B2C-07B2-4C12-8E53-8C5C569ABD44

P2093

Q34163791-64AFAF26-5F10-4C57-A7B3-BA88BE57EAF7

Q34163791-65584B5A-65B5-4FAB-8FA6-B5F75F5A05CC

Q34163791-ACC5E0A1-ECC4-4BEF-96A2-BDDAB0007394

Q34163791-E4F62162-D9A1-42A6-A1EF-38DF11F8A816

Q34163791-EF745E6F-65A7-4A2C-B53A-CF5604CC7031

P2860

Q34163791-19992F79-5340-472B-BB10-EBD785563E8A

Q34163791-3C7A5CA2-9377-4D54-9118-E4EDD6506812

Q34163791-4C128648-054F-4E48-BDD8-C13908A569ED

Q34163791-5299CB91-72B9-4353-AA49-EE83F7F16A10

Q34163791-53E61714-9B0E-489A-9636-27436317704A

Q34163791-779D2AD9-0D7A-4A63-9ABB-A4BFEACD0AA5

Q34163791-8CE0C726-AB58-4655-B5B0-2E6CFF8C37AD

Q34163791-90A49998-2805-466D-95ED-5FAF8E548F0A

Q34163791-9361C4E2-1E8A-4701-801F-78D90CC236DE

Q34163791-A2F39D08-B714-48EE-B4E1-6FEE8EE6FFF6

P304

Q34163791-84BBD7F0-8D78-4B88-A10E-738410922597

P31

Q34163791-43331FD0-D4F8-48DD-B2E5-BBD2FED1CABD

P356

Q34163791-EC24C2B4-68E5-4D93-BB31-7D2A1C027327

P407

Q34163791-1929EDCB-CC18-4A4B-8098-C900C03B80D4

P433

Q34163791-AB48D6FD-CFC1-49CA-BDCA-E6051F4578F9

P478

Q34163791-2BE253C6-BE1C-46C9-9EF3-4310F6DABDEB

P577

Q34163791-F128BD3C-6E7C-443F-AB8B-B53353D84E83

P5875

Q34163791-3D195527-BF4C-4134-BB37-8CE12644F34E

P698

Q34163791-C66932F6-303E-4F40-827F-B51EC8DD6977

P921

Q34163791-1EB9223E-C413-4855-970B-E36ABC4A32E9

P932

Q34163791-FDB2BED4-AC0E-487C-A402-A2913303A395

P356

J.AJOG.2010.05.005

P1433

American Journal of Obstetrics and Gynecology

P1476

Posttherapy residual disease a ...... ecologic Oncology Group study.

@en

P2093

Charles Kunos

http://www.w3.org/2001/XMLSchema#string

Fadi W Abdul-Karim

http://www.w3.org/2001/XMLSchema#string

Frederick B Stehman

http://www.w3.org/2001/XMLSchema#string

Shamshad Ali

http://www.w3.org/2001/XMLSchema#string

Steven Waggoner

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.

Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein

The logrank test.

Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.

Posttherapy surveillance monitoring of cervical cancer by FDG-PET.

Post-irradiation cytology of cervical cancer patients.

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Radiologic measurements of tumor response to treatment: practical approaches and limitations.

Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study.

P304

351.e1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJOG.2010.05.005

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

203

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44666551

http://www.w3.org/2001/XMLSchema#string

P698

20541170

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy

P932

2947558

http://www.w3.org/2001/XMLSchema#string